Recurrent ACVR1 mutations in posterior fossa ependymoma
(2022)
Journal Article
Pratt, D., Lucas, C.-H. G., Selvam, P. P., Abdullaev, Z., Ketchum, C., Quezado, M., …Aldape, K. (2022). Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 144, 373-376. https://doi.org/10.1007/s00401-022-02435-2
All Outputs (3)
MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial (2022)
Journal Article
Rodriguez, D., Calmon, R., Aliaga, E. S., Warren, D., Warmuth-Metz, M., Jones, C., …Jaspan, T. (2022). MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 304(1), 174-182. https://doi.org/10.1148/radiol.211464Background Diffuse midline gliomas (DMG) are characterized by a high incidence of H3 K27 mutations and poorer outcome. The HERBY trial has provided one of the largest cohorts of pediatric DMGs with available radiologic, histologic-genotypic, and surv... Read More about MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma (2018)
Journal Article
Grill, J., Massimino, M., Bouffet, E., Azizi, A. A., McCowage, G., Cañete, A., …Giangaspero, F. (2018). Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. Journal of Clinical Oncology, 36(10), https://doi.org/10.1200/JCO.2017.76.0611Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (... Read More about Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma.